GENMAB A/S -SP ADR (GMAB) Stock Fundamental Analysis
NASDAQ:GMAB - US3723032062 - ADR
24.65 USD
+0.23 (+0.94%)
24.58 USD
-0.07 (-0.28%)
GMAB gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 549 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making GMAB a very profitable company, without any liquidiy or solvency issues. GMAB is growing strongly while it is still valued neutral. This is a good combination! With these ratings, GMAB could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
GMAB had positive earnings in the past year.
In the past year GMAB had a positive cash flow from operations.
In the past 5 years GMAB has always been profitable.
Each year in the past 5 years GMAB had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 17.22%, GMAB belongs to the top of the industry, outperforming 96.17% of the companies in the same industry.
With an excellent Return On Equity value of 21.42%, GMAB belongs to the best of the industry, outperforming 95.99% of the companies in the same industry.
GMAB's Return On Invested Capital of 15.02% is amongst the best of the industry. GMAB outperforms 96.17% of its industry peers.
GMAB had an Average Return On Invested Capital over the past 3 years of 15.20%. This is in line with the industry average of 16.25%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.22% | ||
| ROE | 21.42% | ||
| ROIC | 15.02% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
1.3 Margins
Looking at the Profit Margin, with a value of 35.10%, GMAB belongs to the top of the industry, outperforming 97.09% of the companies in the same industry.
In the last couple of years the Profit Margin of GMAB has declined.
Looking at the Operating Margin, with a value of 33.28%, GMAB belongs to the top of the industry, outperforming 97.63% of the companies in the same industry.
GMAB's Operating Margin has declined in the last couple of years.
GMAB's Gross Margin of 95.12% is amongst the best of the industry. GMAB outperforms 94.54% of its industry peers.
In the last couple of years the Gross Margin of GMAB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.28% | ||
| PM (TTM) | 35.1% | ||
| GM | 95.12% |
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), GMAB is creating value.
GMAB has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, GMAB has less shares outstanding
The debt/assets ratio for GMAB is higher compared to a year ago.
2.2 Solvency
GMAB has an Altman-Z score of 47.73. This indicates that GMAB is financially healthy and has little risk of bankruptcy at the moment.
GMAB's Altman-Z score of 47.73 is amongst the best of the industry. GMAB outperforms 98.36% of its industry peers.
GMAB has a debt to FCF ratio of 0.13. This is a very positive value and a sign of high solvency as it would only need 0.13 years to pay back of all of its debts.
GMAB has a better Debt to FCF ratio (0.13) than 96.54% of its industry peers.
GMAB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
GMAB's Debt to Equity ratio of 0.02 is in line compared to the rest of the industry. GMAB outperforms 41.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.13 | ||
| Altman-Z | 47.73 |
ROIC/WACC2.16
WACC6.94%
2.3 Liquidity
GMAB has a Current Ratio of 5.34. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.34, GMAB is in line with its industry, outperforming 57.56% of the companies in the same industry.
A Quick Ratio of 5.32 indicates that GMAB has no problem at all paying its short term obligations.
GMAB's Quick ratio of 5.32 is in line compared to the rest of the industry. GMAB outperforms 58.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.34 | ||
| Quick Ratio | 5.32 |
3. Growth
3.1 Past
The earnings per share for GMAB have decreased strongly by -56.11% in the last year.
The Earnings Per Share has been growing by 15.75% on average over the past years. This is quite good.
The Revenue has grown by 30.57% in the past year. This is a very strong growth!
Measured over the past years, GMAB shows a very strong growth in Revenue. The Revenue has been growing by 31.16% on average per year.
EPS 1Y (TTM)-56.11%
EPS 3Y15.53%
EPS 5Y15.75%
EPS Q2Q%-75.02%
Revenue 1Y (TTM)30.57%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-82.88%
3.2 Future
GMAB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.81% yearly.
The Revenue is expected to grow by 62.61% on average over the next years. This is a very strong growth
EPS Next Y-77.29%
EPS Next 2Y-48.13%
EPS Next 3Y-30.34%
EPS Next 5Y18.81%
Revenue Next Year20.63%
Revenue Next 2Y18.22%
Revenue Next 3Y16.97%
Revenue Next 5Y62.61%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 41.78, which means the current valuation is very expensive for GMAB.
Compared to the rest of the industry, the Price/Earnings ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 91.80% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.24, GMAB is valued quite expensively.
Based on the Price/Forward Earnings ratio of 80.73, the valuation of GMAB can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 88.71% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.82, GMAB is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 41.78 | ||
| Fwd PE | 80.73 |
4.2 Price Multiples
GMAB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. GMAB is cheaper than 90.35% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, GMAB is valued cheaply inside the industry as 92.17% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 86.67 | ||
| EV/EBITDA | 81.53 |
4.3 Compensation for Growth
GMAB has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as GMAB's earnings are expected to decrease with -30.34% in the coming years.
PEG (NY)N/A
PEG (5Y)2.65
EPS Next 2Y-48.13%
EPS Next 3Y-30.34%
5. Dividend
5.1 Amount
GMAB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
24.65
+0.23 (+0.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners35.41%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap15.16B
Analysts77.24
Price Target99.61 (304.1%)
Short Float %0.61%
Short Ratio2.75
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.16%
Min EPS beat(2)49.64%
Max EPS beat(2)134.67%
EPS beat(4)3
Avg EPS beat(4)44.12%
Min EPS beat(4)-11.29%
Max EPS beat(4)134.67%
EPS beat(8)6
Avg EPS beat(8)30.35%
EPS beat(12)8
Avg EPS beat(12)28.68%
EPS beat(16)11
Avg EPS beat(16)28.52%
Revenue beat(2)1
Avg Revenue beat(2)-2.9%
Min Revenue beat(2)-7.66%
Max Revenue beat(2)1.87%
Revenue beat(4)2
Avg Revenue beat(4)-1.37%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)4.57%
Revenue beat(8)6
Avg Revenue beat(8)0.63%
Revenue beat(12)7
Avg Revenue beat(12)-20.65%
Revenue beat(16)7
Avg Revenue beat(16)-36.38%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)3.98%
EPS NQ rev (3m)-83.3%
EPS NY rev (1m)-84.95%
EPS NY rev (3m)-84.85%
Revenue NQ rev (1m)0.97%
Revenue NQ rev (3m)-85.44%
Revenue NY rev (1m)-85.53%
Revenue NY rev (3m)-85.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 41.78 | ||
| Fwd PE | 80.73 | ||
| P/S | 30.17 | ||
| P/FCF | 86.67 | ||
| P/OCF | 81.58 | ||
| P/B | 18.41 | ||
| P/tB | 30.61 | ||
| EV/EBITDA | 81.53 |
EPS(TTM)0.59
EY2.39%
EPS(NY)0.31
Fwd EY1.24%
FCF(TTM)0.28
FCFY1.15%
OCF(TTM)0.3
OCFY1.23%
SpS0.82
BVpS1.34
TBVpS0.81
PEG (NY)N/A
PEG (5Y)2.65
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.22% | ||
| ROE | 21.42% | ||
| ROCE | 18.45% | ||
| ROIC | 15.02% | ||
| ROICexc | 33.62% | ||
| ROICexgc | 177.57% | ||
| OM | 33.28% | ||
| PM (TTM) | 35.1% | ||
| GM | 95.12% | ||
| FCFM | 34.81% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
ROICexc(3y)68.77%
ROICexc(5y)79.83%
ROICexgc(3y)104.16%
ROICexgc(5y)104.49%
ROCE(3y)18.68%
ROCE(5y)19.78%
ROICexcg growth 3Y22.66%
ROICexcg growth 5Y11.4%
ROICexc growth 3Y-22.7%
ROICexc growth 5Y-14.09%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score7
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.13 | ||
| Debt/EBITDA | 0.11 | ||
| Cap/Depr | 111.43% | ||
| Cap/Sales | 2.17% | ||
| Interest Coverage | 177 | ||
| Cash Conversion | 104.98% | ||
| Profit Quality | 99.17% | ||
| Current Ratio | 5.34 | ||
| Quick Ratio | 5.32 | ||
| Altman-Z | 47.73 |
F-Score7
WACC6.94%
ROIC/WACC2.16
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-56.11%
EPS 3Y15.53%
EPS 5Y15.75%
EPS Q2Q%-75.02%
EPS Next Y-77.29%
EPS Next 2Y-48.13%
EPS Next 3Y-30.34%
EPS Next 5Y18.81%
Revenue 1Y (TTM)30.57%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-82.88%
Revenue Next Year20.63%
Revenue Next 2Y18.22%
Revenue Next 3Y16.97%
Revenue Next 5Y62.61%
EBIT growth 1Y30.8%
EBIT growth 3Y29.8%
EBIT growth 5Y21.02%
EBIT Next Year31.35%
EBIT Next 3Y25.55%
EBIT Next 5Y13.18%
FCF growth 1Y27.91%
FCF growth 3Y51.06%
FCF growth 5Y42.84%
OCF growth 1Y28.41%
OCF growth 3Y47.08%
OCF growth 5Y41.48%